Recognify Life Sciences Inc.

1 trials Commercial sponsor

Filter these 1 trials by condition, phase, country and more.

Open in Search →

1 Registered trials

0 Recruiting

1 Completed trials

3 Countries active

1 Unique IMPs

100% Results reported

Phase II

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Cognitive disorder 1 Schizophrenia 1

Top IMPs

(2R,3S)-2-AMINO-3-HYDROXY-3-PYRIDIN-4-YL-1-PYRROLIDIN-1-YLPROPAN-1-ONE (2R,3R)-2,3-DIHYDROXYBUTANEDIOIC ACID 1

All trials

1 total

An adaptive, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of RL-007 in the treatment of cognitive … Ended

2023-506570-12-01 Phase II 3 countries (2R,3S)-2-AMINO-3-HYDROXY-3-PYRIDIN-4-YL-1-PYRROLIDIN-1-YLPROPAN-1-ONE (2R,3R)-2…

Showing 1–1 of 1 trials

← All sponsors A–Z